Pure Global AI
NCT06225362Recruiting

Quatera 700 vs. Centurion

Evaluation and Clinical Outcomes After Routine Cataract Surgery With the Quatera® 700 and the Centurion® Vision System
Carolina Eyecare Physicians, LLCClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Cataract
Drug/Device/Intervention
Quatera 700
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Carolina Eyecare Physicians, LLC
Location
Mount Pleasant, United States of America
Timeline & enrollment
Phase
N/A
Start date
Jan 10, 2024
End date
Aug 30, 2024
Enrollment
40 participants
Primary outcome

Central corneal thickness,Lens removal time

Summary

Phacoemulsification is the most common treatment for cataract surgery in the developed
 countries and over the years it gained importance due to several factors: small incision,
 surgery performed under topical anesthesia - which reduce injection-related complications -
 short recovery time, low post operatory induced astigmatism, and low incidence of surgical
 complications, when compared to the conventional surgeries. The study evaluates 2 different
 phacoemulsification devices in patients undergoing routine cataract surgery in both eyes.

ICD-10 classifications
Other cataractCataract, unspecifiedComplicated cataractOther specified cataractSenile cataract
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06225362
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06225362 through Pure Global AI's free database. This phase not specified trial is sponsored by Carolina Eyecare Physicians, LLC and is currently Recruiting. The study focuses on Cataract. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.